pentoxifylline and Bacterial Disease studies

Research Excerpts

Excerpt	Relevance	Reference
"To assess the effect of intravenous pentoxifylline as an adjunct to antibiotic therapy on mortality and morbidity in neonates with suspected or confirmed sepsis."	8.91	Pentoxifylline for treatment of sepsis and necrotizing enterocolitis in neonates. ( Haque, KN; Pammi, M, 2015)
"The primary objectives were to assess the effect on mortality and the safety of intravenous pentoxifylline as an adjunct to antibiotic therapy in neonates with suspected or confirmed sepsis and NEC."	8.87	Pentoxifylline for treatment of sepsis and necrotizing enterocolitis in neonates. ( Haque, KN; Pammi, M, 2011)
"The primary objective was to assess the effect on mortality and the safety of intravenous pentoxifylline as an adjunct to antibiotic therapy in neonates with suspected or confirmed sepsis."	8.82	Pentoxifylline for neonatal sepsis. ( Haque, K; Mohan, P, 2003)
"Although pentoxifylline produces various beneficial effects in a preheparinized model of hemorrhagic shock, it was unknown whether this agent restores the depressed cardiac output (CO) and tissue perfusion in a nonheparinized model of trauma-hemorrhage and resuscitation and, if so, whether it decreases the susceptibility to sepsis after hemorrhage."	7.68	Pentoxifylline restores cardiac output and tissue perfusion after trauma-hemorrhage and decreases susceptibility to sepsis. ( Ba, ZF; Chaudry, IH; Tait, SM; Wang, P; Zhou, M, 1993)
"Pentoxifylline (PTX) is a derivative of methyl xanthine and has several beneficial effects in sepsis."	5.31	The effects of pentoxifylline on bacterial translocation after intestinal obstruction. ( Gokce, O; Gulay, Z; Kocdor, H; Kocdor, MA, 2002)
"Pentoxifylline treatment just after shed blood transfusion significantly attenuated this phenomenon."	5.31	The effects of pentoxifylline treatment on bacterial translocation after hemorrhagic shock in rats. ( Arpacik, M; Bakici, MZ; Elagöz, S; Köylüoglu, G, 2001)
"To assess the effect of intravenous pentoxifylline as an adjunct to antibiotic therapy on mortality and morbidity in neonates with suspected or confirmed sepsis."	4.91	Pentoxifylline for treatment of sepsis and necrotizing enterocolitis in neonates. ( Haque, KN; Pammi, M, 2015)
"The primary objectives were to assess the effect on mortality and the safety of intravenous pentoxifylline as an adjunct to antibiotic therapy in neonates with suspected or confirmed sepsis and NEC."	4.87	Pentoxifylline for treatment of sepsis and necrotizing enterocolitis in neonates. ( Haque, KN; Pammi, M, 2011)
"The primary objective was to assess the effect on mortality and the safety of intravenous pentoxifylline as an adjunct to antibiotic therapy in neonates with suspected or confirmed sepsis."	4.82	Pentoxifylline for neonatal sepsis. ( Haque, K; Mohan, P, 2003)
"Although pentoxifylline produces various beneficial effects in a preheparinized model of hemorrhagic shock, it was unknown whether this agent restores the depressed cardiac output (CO) and tissue perfusion in a nonheparinized model of trauma-hemorrhage and resuscitation and, if so, whether it decreases the susceptibility to sepsis after hemorrhage."	3.68	Pentoxifylline restores cardiac output and tissue perfusion after trauma-hemorrhage and decreases susceptibility to sepsis. ( Ba, ZF; Chaudry, IH; Tait, SM; Wang, P; Zhou, M, 1993)
"Treatment with pentoxifylline was the only factor associated with liver-related complications."	2.75	Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced cirrhosis. ( Barraud, H; Carbonell, N; Condat, B; Lebrec, D; Moreau, R; Oberti, F; Perarnau, JM; Poynard, T; Ramond, MJ; Renard, P; Saliba, F; Thabut, D, 2010)
"Pentoxifylline-treated animals had a statistically significant reduction of inflammatory cytokine levels, pancreatic histological damage, occurrence of bacterial translocation and pancreatic infection (p < 0."	1.35	Do the effects of pentoxifylline on the inflammatory process and pancreatic infection justify its use in acute pancreatitis? ( Coelho, AM; Cunha, JE; Jukemura, J; Machado, MC; Matheus, AS; Patzina, RA; Sampietre, S, 2009)
"Pentoxifylline (PTX) is a derivative of methyl xanthine and has several beneficial effects in sepsis."	1.31	The effects of pentoxifylline on bacterial translocation after intestinal obstruction. ( Gokce, O; Gulay, Z; Kocdor, H; Kocdor, MA, 2002)
"Pentoxifylline treatment just after shed blood transfusion significantly attenuated this phenomenon."	1.31	The effects of pentoxifylline treatment on bacterial translocation after hemorrhagic shock in rats. ( Arpacik, M; Bakici, MZ; Elagöz, S; Köylüoglu, G, 2001)
"Pentoxifylline pretreatment significantly improved the measurements of left lung edema and epithelial and endothelial permeability."	1.30	The effects of two antiinflammatory pretreatments on bacterial-induced lung injury. ( Broaddus, VC; Hattori, S; Kravchenko, V; Kudoh, I; Mathison, JC; Miyazaki, H; Nishizawa, H; Pittet, JF; Sawa, T; Wiener-Kronish, JP; Yamada, H; Yamakawa, T, 1999)

Research

Studies (14)

Authors

Clinical Trials (3)

Trial Overview

Trial Outcomes

Alanine Amino Transferase (ALT) Levels at 2 Years of Life

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	6 (42.86)	18.2507
2000's	5 (35.71)	29.6817
2010's	3 (21.43)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
Pammi, M	2
Haque, KN	2
Piskun, VD	1
Matheus, AS	1
Coelho, AM	1
Sampietre, S	1
Jukemura, J	1
Patzina, RA	1
Cunha, JE	1
Machado, MC	1
Lebrec, D	1
Thabut, D	1
Oberti, F	1
Perarnau, JM	1
Condat, B	1
Barraud, H	1
Saliba, F	1
Carbonell, N	1
Renard, P	1
Ramond, MJ	1
Moreau, R	1
Poynard, T	1
Kocdor, MA	1
Kocdor, H	1
Gulay, Z	1
Gokce, O	1
Haque, K	1
Mohan, P	1
Refsum, SE	1
Norwood, W	1
Rowlands, BJ	1
Boston, VE	1
Wang, P	1
Ba, ZF	1
Zhou, M	1
Tait, SM	1
Chaudry, IH	1
Castañon-Gonzalez, JA	1
Eid-Lidt, G	1
Wacher, N	1
Gallegos-Perez, H	1
Miranda-Ruiz, R	1
Ferrà, C	1
de Sanjosé, S	1
Lastra, CF	1
Martí, F	1
Mariño, EL	1
Sureda, A	1
Brunet, S	1
Gallardo, D	1
Berlanga, JJ	1
García, J	1
Grañena, A	1
Estey, EH	1
Thall, PF	1
Reed, P	1
Kantarjian, H	1
Beran, M	1
Pierce, S	1
Keating, MJ	1
Miyazaki, H	1
Broaddus, VC	1
Wiener-Kronish, JP	1
Sawa, T	1
Pittet, JF	1
Kravchenko, V	1
Mathison, JC	1
Nishizawa, H	1
Hattori, S	1
Yamakawa, T	1
Yamada, H	1
Kudoh, I	1
Köylüoglu, G	1
Bakici, MZ	1
Elagöz, S	1
Arpacik, M	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Pentoxifylline Dose Optimization in Preterm Neonatal Late Onset Sepsis[NCT04152980]	Phase 3	40 participants (Anticipated)	Interventional	2020-01-12	Recruiting
Clinical Trial of Pentoxifylline Administration Versus Placebo on Survival in Patients With Cirrhosis and Severe Liver Failure[NCT00162552]	Phase 3	342 participants (Actual)	Interventional	2004-08-31	Completed
A Phase II Trial of Pentoxifylline in Newly-Diagnosed Biliary Atresia[NCT01774487]	Phase 2	17 participants (Actual)	Interventional	2013-02-04	Terminated (stopped due to Target enrollment was not reached because the medication, pentoxifylline, has a taste that is not well tolerated by infants. The study team decided to end the study before meeting the enrollment goal because of the medication taste.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

The investigators will record the ALT levels at age two years, in patients who had previously been treated with PTX therapy and still have their native liver. Scale 14-45 U/L, with a higher level indicating a worse outcome. (NCT01774487)
Timeframe: 2 years of age

Number of Participants Achieving Zero or Positive Weight Z-scores 12 Weeks After Starting PTX Therapy

Intervention	U/L (Mean)
Pentoxifylline - Group 1	160

The investigators will track the weight of patients over the course of therapy in patients receiving 90 days of PTX (this is recorded as part of routine clinical care). The weight will then be compared to standards to calculate a z-score. Normal weight Z-score is greater than or equal to 0, with a higher number of patients meeting this indicating a better outcome. (NCT01774487)
Timeframe: 12 weeks after starting therapy

Number of Participants With Normal Serum Conjugated Bilirubin Levels 12 Weeks After Starting PTX (Pentoxifylline) Therapy

Intervention	Participants (Count of Participants)
Pentoxifylline - Group 1	0
Group 2	0

The investigators will track the serum conjugated bilirubin (CB) levels over the course of therapy in patients receiving 90 days of PTX (this laboratory test is drawn as part of routine care). Normal CB is 0.0-0.3 mg/dL, with a higher number of patients meeting this indicating a better outcome. (NCT01774487)
Timeframe: 12 weeks after starting therapy

Platelet Levels at 2 Years of Life

Intervention	Participants (Count of Participants)
Pentoxifylline - Group 1	6
Pentoxifylline - Group 2	0

The investigators will record platelet levels at age two years, in patients who had previously been treated with PTX therapy and still have their native liver. Scale 189-403*10^3 Platelets/μL, with a lower level indicating a worse outcome. (NCT01774487)
Timeframe: 2 years of age

Spleen Size at 2 Years of Age

Intervention	10^3 Platelets/μL (Mean)
Pentoxifylline - Group 1	208

"The investigators will measure spleen size by ultrasound at 2 years of age, in patients who had received PTX therapy earlier and still have their native liver. Normal spleen size range (10th-90th percentile) at this age is 6.4-8.6 cm, with a value exceeding this range indicating a worse outcome." (NCT01774487)
Timeframe: 2 years of age

Time to Liver Transplant

Intervention	cm (Mean)
Pentoxifylline - Group 1	10.0

The investigators will track time to liver transplant. The shorter time to liver transplant indicates a worse outcome. (NCT01774487)
Timeframe: Baseline and up to two years after therapy finishes

Article	Year
Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced cirrhosis. Gastroenterology, 2010, Volume: 138, Issue:5 Topics: Administration, Oral; Adult; Aged; Bacterial Infections; Double-Blind Method; France; Gastrointestin	2010
Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced cirrhosis. Gastroenterology, 2010, Volume: 138, Issue:5 Topics: Administration, Oral; Adult; Aged; Bacterial Infections; Double-Blind Method; France; Gastrointestin	2010
Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced cirrhosis. Gastroenterology, 2010, Volume: 138, Issue:5 Topics: Administration, Oral; Adult; Aged; Bacterial Infections; Double-Blind Method; France; Gastrointestin	2010
Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced cirrhosis. Gastroenterology, 2010, Volume: 138, Issue:5 Topics: Administration, Oral; Adult; Aged; Bacterial Infections; Double-Blind Method; France; Gastrointestin	2010
Pentoxifylline and oxygen consumption in severe sepsis--a preliminary report. Acta anaesthesiologica Scandinavica. Supplementum, 1995, Volume: 107 Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Bacterial Infections; Cardiac Output; Critical	1995
Pentoxifylline, ciprofloxacin and prednisone failed to prevent transplant-related toxicities in bone marrow transplant recipients and were associated with an increased incidence of infectious complications. Bone marrow transplantation, 1997, Volume: 20, Issue:12 Topics: Adolescent; Adult; Anti-Infective Agents; Anti-Inflammatory Agents; Bacterial Infections; Bone Marro	1997
Treatment of newly diagnosed AML, RAEB-t or RAEB with lisofylline or placebo in addition to chemotherapy. Leukemia, 1999, Volume: 13, Issue:6 Topics: Acute Disease; Aged; Anemia, Refractory, with Excess of Blasts; Anti-Infective Agents; Antineoplasti	1999

Article	Year
[Optimization of treatment of bacterial intestinal infections associated with expressed dehydration]. Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology, 2008, Issue:6 Topics: Bacterial Infections; Combined Modality Therapy; Dehydration; Enterocolitis; Enzyme Inhibitors; Flui	2008
Do the effects of pentoxifylline on the inflammatory process and pancreatic infection justify its use in acute pancreatitis? Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], 2009, Volume: 9, Issue:5 Topics: Animals; Bacterial Infections; Cytokines; Inflammation; Male; Pancreas; Pancreatitis, Acute Necrotiz	2009
The effects of pentoxifylline on bacterial translocation after intestinal obstruction. Shock (Augusta, Ga.), 2002, Volume: 18, Issue:2 Topics: Analysis of Variance; Animals; Bacterial Infections; Bacterial Translocation; Chi-Square Distributio	2002
Pentoxifylline improves resting membrane potential in sepsis. Journal of pediatric surgery, 1993, Volume: 28, Issue:9 Topics: Animals; Bacterial Infections; Drug Administration Schedule; Female; Membrane Potentials; Muscles; P	1993
Pentoxifylline restores cardiac output and tissue perfusion after trauma-hemorrhage and decreases susceptibility to sepsis. Surgery, 1993, Volume: 114, Issue:2 Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Bacterial Infections; Blood Pressure; Ca	1993
The effects of two antiinflammatory pretreatments on bacterial-induced lung injury. Anesthesiology, 1999, Volume: 90, Issue:6 Topics: Animals; Anti-Inflammatory Agents; Bacterial Infections; Goats; Immune Sera; Interleukin-8; Lung Dis	1999
The effects of pentoxifylline treatment on bacterial translocation after hemorrhagic shock in rats. Clinical and experimental medicine, 2001, Volume: 1, Issue:1 Topics: Animals; Bacterial Infections; Bacterial Translocation; Blood; Blood Transfusion, Autologous; Cecum;	2001

pentoxifylline and Bacterial Disease